Corrigendum "Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study" [British Journal of Haematology, 169(4), (2015), 534-543, DOI: 10.1111/bjh.13323];Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study

British Journal of Haematology

Volumn 169, Issue 4, 2015, Pages 534-543

  Swords, Ronan T ^a   Erba, Harry P ^b   Deangelo, Daniel J ^c   Bixby, Dale L ^b   Altman, Jessica K ^d   Maris, Michael ^e   Hua, Zhaowei ^f   Blakemore, Stephen J ^f   Faessel, Hélène ^f   Sedarati, Farhad ^f   Dezube, Bruce J ^f   Giles, Francis J ^d   Medeiros, Bruno C ^g  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Rocky Mountain Blood and Marrow Transplant Program   (United States)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukaemia; MLN4924; NEDD8; NEDD8 activating enzyme; Pevonedistat

Indexed keywords

PEVONEDISTAT; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; PYRIMIDINE DERIVATIVE; UBA3 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILL; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CRACKLE; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE; GENE EXPRESSION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOXIA; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NQO1 GENE; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; TOXIC HEPATITIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYCLOPENTANES; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROMES; PYRIMIDINES; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84928426387     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13775     Document Type: Erratum

References (51)

1. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417-421.
2. Bhatia, S., Hamid, O., Pavlick, A.C., Mulligan, G., Smith, P.G., Pickard, M., Shultz, M., Walker, R.M., Dezube, B. & O'Day, S. (2011) MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: results of a phase I study. Journal of Clinical Oncology, 29, 8529, (suppl; abstr 8529).
3. Bloom, J. & Pagano, M. (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Seminars in Cancer Biology, 13, 41-47.
4. Brownell, J.E., Sintchak, M.D., Gavin, J.M., Liao, H., Bruzzese, F.J., Bump, N.J., Soucy, T.A., Milhollen, M.A., Yang, X., Burkhardt, A.L., Ma, J., Loke, H.K., Lingaraj, T., Wu, D., Hamman, K.B., Spelman, J.J., Cullis, C.A., Langston, S.P., Vyskocil, S., Sells, T.B., Mallender, W.D., Visiers, I., Li, P., Claiborne, C.F., Rolfe, M., Bolen, J.B. & Dick, L.R. (2010) Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Molecular Cell, 37, 102-111.
5. Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 1114-1124.
6. Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, R.K. & Wheatley, K. (2009) The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology, 145, 318-332.
7. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R. & Hills, R.K. (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Journal of Clinical Oncology, 28, 2389-2395.
8. Byrd, J.C., Mrózek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325-4336.
9. Chen, G. & Li, G. (2010) Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. International Journal of Oncology, 37, 1339-1344.
10. Chen, G., Cheng, Y., Martinka, M. & Li, G. (2010) Cul1 expression is increased in early stages of human melanoma. Pigment Cell & Melanoma Research, 23, 572-574.
11. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Büchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
12. Chiba, T. & Tanaka, K. (2004) Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Current Protein and Peptide Science, 5, 177-184.
13. Ciechanover, A. (2005) Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). Angewandte Chemie (International ed. in English), 44, 5944-5967.
14. Crusio, K.M., King, B., Reavie, L.B. & Aifantis, I. (2010) The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene, 29, 4865-4873.
15. Fanucchi, M.P., Fossella, F.V., Belt, R., Natale, R., Fidias, P., Carbone, D.P., Govindan, R., Raez, L.E., Robert, F., Ribeiro, M., Akerley, W., Kelly, K., Limentani, S.A., Crawford, J., Reimers, H.J., Axelrod, R., Kashala, O., Sheng, S. & Schiller, J.H. (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology, 24, 5025-5033.
16. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., M.Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867-4874.
17. Gong, L. & Yeh, E.T. (1999) Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. Journal of Biological Chemistry, 274, 12036-12042.
18. Goy, A., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Nasta, S., O'Connor, O., Shi, H., Boral, A.L. & Fisher, R.I. (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 20, 520-525.
19. Gstaiger, M., Lim, M., Jordan, R., Catzavelos, C., Mestan, J., Slingerland, J. & Krek, W. (2001) Skp2 is oncogenic and overexpressed in human cancers. Proceedings of the National Academy of Sciences, 98, 5043-5048.
20. Harvey, R.D., Lebovic, D., Lonial, S., Jakubowiak, J., Pickard, M., McDonald, A., Mulligan, G., Blakemore, S., Kuan, S., Dezube, B. & O'Connor, O. (2010) MLN4924, an investigational NEDD8-activating (NAE) inhibitor, inpatients with relapsed and/or refractory lymphoma or multiple myeloma (MM): Phase I dose escalation study of twice-weekly dosing. Haematologica, 95[suppl.2]: 160. abs. 0394.
21. Herrmann, J., Lerman, L.O. & Lerman, A. (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circulation Research, 100, 1276-1291.
22. Hershko, A. (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death and Differentiation, 12, 1191-1197.
23. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436.
24. Kauh, J.S., Cohen, R., Clarke, J.W., Harvey, R., Mulligan, G., Venkatakrishnan, K., Berger, A., Smith, P.G., Petruzelli, L. & Sarantopoulos, J. (2009) Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin. Journal of Clinical Oncology 27, 15s (suppl: abstr 2562)
25. Kauh, J.S., Shapiro, G., Cohen, R.B., Clark, J.W., Harvey, R.D., Cleary, J.M., Mahalingam, D., Kuan, S., McDonald, A., Berger, A., Dezube, B. & Saratopoulos, J. (2011) MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: phase I study of multiple treatment schedules. Journal of Clinical Oncology 29, 17s (suppl: abstr 3013).
26. Kondagunta, G.V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M. & Motzer, R.J. (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 22, 3720-3725.
27. Lin, J.J., Milhollen, M.A., Smith, P.G., Narayanan, U. & Dutta, A. (2010) NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Research, 70, 10310-10320.
28. Milhollen, M.A., Traore, T., Adams-Duffy, J., Thomas, M.P., A.Berger, A.J., Dang, L., Dick, L.R., Garnsey, J.J., Koenig, E., Langston, S.P., Manfredi, M., Narayanan, U., Rolfe, M., Staudt, L.M., Soucy, T.A., Yu, J., Zhang, J., Bolen, J.B. & Smith, P.G. (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood, 116, 1517-1524.
29. Milhollen, M.A., Narayanan, U., Soucy, T.A., Veiby, P.O., Smith, P.G. & Amidon, B. (2011) Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Research, 71, 3042-3051.
30. Milhollen, M.A., Thomas, M.P., Narayanan, U., Traore, T., Riceberg, J. & Amidon, B.S. (2012) Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell, 21, 388-401.
31. National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP): National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Version 3, 09 August 2006, 2011.
32. Nawrocki, S., Kelly, K., Oberheu, K., Mahalingam, D., Smith, P.G. & Carew, J.S. (2010) Disrupting NEDD8-mediated protein turnover with MLN4924 significantly augments the efficacy of cytarabine. Blood, 116, 1335a, 2010 (suppl; abstr 3255)
33. Petroski, M.D. & Deshaies, R.J. (2005) Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews Molecular Cell Biology, 6, 9-20.
34. Podust, V.N., Brownell, J.E., Gladysheva, T.B., Luo, R.S., Wang, C., Coggins, M.B., Pierce, J.W., Lightcap, E.S. & Chau, V. (2000) A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proceedings of the National Academy of Sciences, 97, 4579-4584.
35. Read, M.A., Brownell, J.E., Gladysheva, T.B., Hottelet, M., Parent, L.A., Coggins, M.B., Pierce, J.W., Podust, V.N., Luo, R.S., Chau, V. & Palombella, V.J. (2000) Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Molecular and Cellular Biology, 20, 2326-2333.
36. Reece, D.E., U. Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Bladé, J., Fermand, J.P., Hassoun, H., Heffner, L., Vescio, R.A., Liu, K., Enny, C., Esseltine, D.L., van de Velde, H., Cakana, A. & Comenzo, R.L. (2001) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 118, 865-873.
37. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
38. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
39. Shah, J., Jakubowiak, A.J., O'Connor, O., Orlowski, R., Patterson, M. & Harvey, D. (2009) Phase 1 dose escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-hodgkin lymphoma. American Society of Hematology, 114, abs #1854
40. Shinde, V., Burke, K.E., Chakravarty, A., Fleming, M., McDonald, A.A., Berger, A., Ecsedy, J., Blakemore, S., Tirrell, S.M. & Bowman, D. (2014) Applications of pathology-assisted image analysis of immunohistochemistry-based biomarkers in oncology. Veterinary Pathology, 51, 292-303.
41. Smith, P.G., Traore, T., Grossman, S., Narayanan, U., Carew, J.S. & Lublinksky, A. (2011) Azacitidine/Decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML Models. American Society of Hematology Annual Meeting, 118, 578. abstr 615.
42. Soucy, T.A., Smith, P.G., Milhollen, M.A., Berger, A.J., Gavin, J.M., Adhikari, S., Brownell, J.E., Burke, K.E., Cardin, D.P., Critchley, S., Cullis, C.A., Doucette, A., Garnsey, J.J., Gaulin, J.L., Gershman, R.E., Lublinsky, A.R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E.J., Peluso, S., Rezaei, M., Sintchak, M.D., Talreja, T., Thomas, M.P., Traore, T., Vyskocil, S., Weatherhead, G.S., Yu, J., Zhang, J., Dick, L.R., Claiborne, C.F., Rolfe, M., Bolen, J.B. & Langston, S.P. (2009a) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 458, 732-736.
43. Soucy, T.A., Smith, P.G. & Rolfe, M. (2009b) Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clinical Cancer Research, 15, 3912-3916.
44. Soucy, T.A., Dick, L.R., Smith, P.G., Milhollen, M.A. & Brownell, J.E. (2010) The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer, 1, 708-716.
45. Swords, R.T., Kelly, K.R., Smith, P.G., Garnsey, J.J., Mahalingam, D., Medina, E., Oberheu, K., Padmanabhan, S., O'Dwyer, M., Nawrocki, S.T., Giles, F. & Carew, J.S. (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 115, 3796-3800.
46. Swords, R., Savona, M., Maris, M., Erba, H.P., Zhaowei, Z., Faessel, H., Blakemore, S., Sederati, F., Dezube, B. & Medeiros, B. (2014) First-in-class NAE inhibitor pevonedistat (MLN4924), in combination with azacitadine for acute myeloid leukemia (AML) patients consdiered unfit for conventional chemtherapy: results from the C15009 trial. Haematologica, 99[suppl.1]: 223-224. abs # 4024.
47. Traore, T., Mihollen, M., Garnsey, J., Berger, A., Manfredi, M. & Cosmopolous, K. (2010) Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma. Journal of Clinical Oncology 29, 16s (suppl; abstr 8594).
48. Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R. & Badros, A. (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical Cancer Research, 13, 3320-3325.
49. Walker, R.M., Koenig, E., Mulligan, G., Lightcap, E., Pickard, M.D. & Smith, P.G. (2011) Development, validation, and clinical implementation of a peripheral blood RT-PCR pharmacodynamic assay for MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE). Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011; (suppl; abstr 196).
50. Wang, M., Medeiros, B.C., Erba, H.P., DeAngelo, D.J., Giles, F.J. & Swords, R.T. (2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opinion on Therapeutic Targets, 15, 253-264.
51. Wolenski, F., Fisher, C., Sano, T., Varrone, G., Wyllie, S. & Ciccia, L. (2013) The NAE Inhibitor MLN4924 Synergizes with TNF-a to Induce Death Through Apoptosis and Necroptosis in a Rat Hepatoma Cell Line. August 11-16, Andover, NH, poster presentation.